Online inquiry

IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11968MR)

This product GTTS-WQ11968MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3&IGF1R gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1; NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065; 3480
UniProt ID P21860; P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11968MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6570MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ5613MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ6649MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DI-17E6
GTTS-WQ699MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ5375MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ11691MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ14548MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ12870MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OPN-305
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW